Glutathione levels in human tumors

Biomarkers

Volumn 17, Issue 8, 2012, Pages 671-691

  Gamcsik, Michael P ^a   Kasibhatla, Mohit S ^b   Teeter, Stephanie D ^a   Colvin, O Michael ^b  

^a North Carolina 27599 and North Carolina State University   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

Antioxidant; Biomarker; Cancer; Oxidative stress; Patients; Response

Indexed keywords

BIOLOGICAL MARKER; GLUTATHIONE;

BRAIN CANCER; BREAST CANCER; CANCER GRADING; CANCER STAGING; CANCER TISSUE; COLORECTAL CANCER; CORRELATION ANALYSIS; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; LIVER TUMOR; LUNG CANCER; OVARY CANCER; OXIDATIVE STRESS; PROGNOSIS; REVIEW; STOMACH CANCER; SURVIVAL TIME; SYSTEMATIC REVIEW; TISSUE LEVEL; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; GLUTATHIONE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; NEOPLASMS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870514054     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.715672     Document Type: Review

References (146)

1. Abel S, De Kock M, van Schalkwyk DJ, Swanevelder S, Kew MC, Gelderblom WC. (2009). Altered lipid profile, oxidative status and hepatitis B virus interactions in human hepatocellular carcinoma. Prostaglandins Leukot Essent Fatty Acids 81:391-399.
2. Abou Ghalia AH, Fouad IM. (2000). Glutathione and its metabolizing enzymes in patients with different benign and malignant diseases. Clin Biochem 33:657-662.
3. Ahmed MI, Fayed ST, Hossein H, Tash FM. (1999). Lipid peroxidation and antioxidant status in human cervical carcinoma. Dis Markers 15:283-291.
4. Albin N, Massaad L, Toussaint C, Mathieu MC, Morizet J, Parise O, Gouyette A, Chabot GG. (1993). Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues. Cancer Res 53:3541-3546.
5. Allalunis-Turner MJ, Barron GM, Day RS 3rd, Fulton DS, Urtasun RC. (1992). Radiosensitivity testing of human primary brain tumor specimens. Int J Radiat Oncol Biol Phys 23:339-343.
6. Allalunis-Turner MJ, Day RS 3rd, McKean JD, Petruk KC, Allen PB, Aronyk KE, Weir BK, Huyser-Wierenga D, Fulton DS, Urtasun RC. (1991). Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells. J Neurooncol 11:157-164.
7. Bailey HH. (1998). L-S,R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact 111-112:239-254.
8. Balasenthil S, Saroja M, Ramachandran CR, Nagini S. (2000). Of humans and hamsters: comparative analysis of lipid peroxidation, glutathione, and glutathione-dependent enzymes during oral carcinogenesis. Br J Oral Maxillofac Surg 38:267-270.
9. Balasubramaniyan N, Subramanian S, Govindasamy S. (1994). Status of antioxidant systems in human carcinoma of uterine cervix. Cancer Lett 87:187-192.
10. Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL. (2009). Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 390:191-214.
11. Barranco SC, Perry RR, Durm ME, Quraishi M, Werner AL, Gregorcyk SG, Kolm P. (2000). Relationship between colorectal cancer glutathione levels and patient survival: early results. Dis Colon Rectum 43:1133-1140.
12. Barranco SC, Perry RR, Durm ME, Werner AL, Gregorcyk SG, Bolton WE, Kolm P, Townsend CM Jr. (1994). Intratumor variability in prognostic indicators may be the cause of conflicting estimates of patient survival and response to therapy. Cancer Res 54:5351-5356.
13. Bartsch H, Petruzzelli S, De Flora S, Hietanen E, Camus AM, Castegnaro M, Alexandrov K, Rojas M, Saracci R, Giuntini C. (1992). Carcinogen metabolism in human lung tissues and the effect of tobacco smoking: results from a case-control multicenter study on lung cancer patients. Environ Health Perspect 98:119-124.
14. Baur G, Wendel A. (1980). The activity of the peroxide-metabolizing system in human colon carcinoma. J Cancer Res Clin Oncol 97:267-273.
15. Berger SJ, Gosky D, Zborowska E, Willson JK, Berger NA. (1994). Sensitive enzymatic cycling assay for glutathione: measurements of glutathione content and its modulation by buthionine sulfoximine in vivo and in vitro in human colon cancer. Cancer Res 54:4077-4083.
16. Blair SL, Heerdt P, Sachar S, Abolhoda A, Hochwald S, Cheng H, Burt M. (1997). Glutathione metabolism in patients with non-small cell lung cancers. Cancer Res 57:152-155.
17. Bluhm C, Greschuchna D. (1989). Fate of glutathione, related enzyme activities and in vitro lymphocyte transformation in patients with bronchial carcinoma. In: Garner RC, Hradec J, eds. Biochemistry of Chemical Carcinogenesis. New York: Plenum Press.
18. Britten RA, Green JA, Warenius HM. (1992). Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int J Radiat Oncol Biol Phys 24:527-531.
19. Burhans WC, Heintz NH. (2009). The cell cycle is a redox cycle: linking phase-specific targets to cell fate. Free Radic Biol Med 47:1282-1293.
20. Buser K, Joncourt F, Altermatt HJ, Bacchi M, Oberli A, Cerny T. (1997). Breast cancer: pretreatment drug resistance parameters (GSHsystem, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics. Ann Oncol 8:335-341.
21. Butler RN, Butler WJ, Moraby Z, Fettman MJ, Khoo KK, Roberts- Thomson IC. (1994). Glutathione concentrations and glutathione S-transferase activity in human colonic neoplasms. J Gastroenterol Hepatol 9:60-63.
22. Caglar M, Ciftci I, Hosal S, Kilinc K, Ercan MT. (2001). Detection of head and neck cancer with 99Tcm glutathione: a correlative study with tissue glutathione and glutathione S-transferase. Nucl Med Commun 22:33-38.
23. Calderon-Solt L, Solt DB. (1985). Gamma-glutamyl transpeptidase in precancerous lesions and carcinomas of oral, pharyngeal, and laryngeal mucosa. Cancer 56:138-143.
24. Cantin AM, North SL, Hubbard RC, Crystal RG. (1987). Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol 63:152-157.
25. Chang TC, Chang MJ, Hsueh S. (1993). Glutathione concentration and distribution in cervical cancers and adjacent normal tissues. Gynecol Obstet Invest 36:52-55.
26. Cheng X, Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Okada M, Terakawa N. (1997). Glutathione S-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy. Cancer 79:521-527.
27. Coban T, Mabsout A, Eke BC, Bülbül D, Berberoglu U, Iscan M. (1998). Glutathione and lipid peroxidation levels in human breast tumors. Neoplasma 45:151-156.
28. Conklin KA. (2004). Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 3:294-300.
29. Constantin A, Elkhaled A, Jalbert L, Srinivasan R, Cha S, Chang SM, Bajcsy R, Nelson SJ. (2012). Identifying malignant transformations in recurrent low grade gliomas using high resolution magic angle spinning spectroscopy. Artif Intell Med 55:61-70.
30. Cook JA, Pass HI, Iype SN, Friedman N, DeGraff W, Russo A, Mitchell JB. (1991). Cellular glutathione and thiol measurements from surgically resected human lung tumor and normal lung tissue. Cancer Res 51:4287-4294.
31. Corrocher R, Casaril M, Bellisola G, Gabrielli GB, Nicoli N, Guidi GC, De Sandre G. (1986). Severe impairment of antioxidant system in human hepatoma. Cancer 58:1658-1662.
32. Czeczot H, Scibior D, Skrzycki M, Podsiad M. (2005). [Antioxidant barrier in patients with gastric cancer-preliminary study]. Pol Merkur Lekarski 19:521-525.
33. Czeczot H, Scibior D, Skrzycki M, Podsiad M. (2006). Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma. Acta Biochim Pol 53:237-242.
34. Czeczot H, Skrzycki M, Gawryszewska E, Podsiad M, Porembska Z. (2003). [Evaluation of antioxidant status in patients with primary hepatocellular carcinoma]. Pol Merkur Lekarski 15:118-122.
35. Demir S, Yilmaz M, Köseoglu M, Akalin N, Aslan D, Aydin A. (2003). Role of free radicals in peptic ulcer and gastritis. Turk J Gastroenterol 14:39-43.
36. Djuric Z, Malviya VK, Deppe G, Malone JM Jr, McGunagle DL, Heilbrun LK, Reading BA, Lawrence WD. (1990). Detoxifying enzymes in human ovarian tissues: comparison of normal and tumor tissues and effects of chemotherapy. J Cancer Res Clin Oncol 116:379-383.
37. Duarte IF, Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Carreira IM, Bernardo J, Gomes A, Sousa V, Carvalho L. (2010). Can nuclear magnetic resonance (NMR) spectroscopy reveal different metabolic signatures for lung tumours? Virchows Arch 457:715-725.
38. Dudek H, Farbiszewski R, Lebkowski WJ, Michno T, Kozlowski A. (2001). [Concentration of glutathione (GSH), ascorbic acid (Vit. C), and thiobarbiturate acid reacting components (MDA) in brain neoplasms]. Wiad Lek 54:615-620.
39. Dudek H, Farbiszewski R, Michno T, Witek A, Kozlowski A, Rydzewska M. (2002). The decrease in antioxidant potential in human brain tumours. Rocz Akad Med Bialymst 47:113-122.
40. Dudek H, Farbiszewski R, Rydzewska M, Michno T, Kozlowski A. (2004). Evaluation of antioxidant enzymes activity and concentration of non-enzymatic antioxidants in human brain tumours. Wiad Lek 57:16-19.
41. Dudek H, Farbiszewski R, Rydzewska M, Michno T, Kozlowski A. (2005). [Concentration of glutathione (GSH), ascorbic acid (vitamin C) and substances reacting with thiobarbituric acid (TBA-rs) in single human brain metastases]. Wiad Lek 58:379-381.
42. Durham JR, Frierson HF Jr, Hanigan MH. (1997). Gamma-glutamyl transpeptidase immunoreactivity in benign and malignant breast tissue. Breast Cancer Res Treat 45:55-62.
43. Eapen CE, Madesh M, Balasubramanian KA, Pulimood A, Mathan M, Ramakrishna BS. (1998). Mucosal mitochondrial function and antioxidant defences in patients with gastric carcinoma. Scand J Gastroenterol 33:975-981.
44. el-Sharabasy MM, el-Dosoky I, Horria H, Khalaf AH. (1993). Elevation of glutathione, glutathione-reductase and nucleic acids in both normal tissues and tumour of breast cancer patients. Cancer Lett 72:11-15.
45. Engin A, Ferahköse Z. (1990). Liver glutathione contents in patients with gastric adenocarcinomas. Tumori 76:48-50.
46. Evans SM, Lew R, Kochman ML, Wileyto EP, Baum E, Safford KM, Koch CJ. (2002). Human esophogeal cancer is distinguished from adjacent esophogeal tissue by tissue cysteine concentrations. Digest Dis Sci 47:2743-2750.
47. Ferruzzi E, Franceschini R, Cazzolato G, Geroni C, Fowst C, Pastorino U, Tradati N, Tursi J, Dittadi R, Gion M. (2003). Blood glutathione as a surrogate marker of cancer tissue glutathione S-transferase activity in non-small cell lung cancer and squamous cell carcinoma of the head and neck. Eur J Cancer 39:1019-1029.
48. Fiaschi AI, Cozzolino A, Ruggiero G, Giorgi G. (2005). Glutathione, ascorbic acid and antioxidant enzymes in the tumor tissue and blood of patients with oral squamous cell carcinoma. Eur Rev Med Pharmacol Sci 9:361-367.
49. Ghazal-Aswad S, Hogarth L, Hall AG, George M, Sinha DP, Lind M, Calvert AH, Sunter JP, Newell DR. (1996). The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients. Br J Cancer 74:468-473.
50. Grubben MJ, van den Braak CC, Nagengast FM, Peters WH. (2006). Low colonic glutathione detoxification capacity in patients at risk for colon cancer. Eur J Clin Invest 36:188-192.
51. Guichard M, Lespinasse F, Estelin R, Gerbaulet A, Haie C, Lartigau E, Malaise EP, Micheau C, Prade M, Richard JM. (1990). Glutathione and cysteine levels in human tumour biopsies. Br J Radiol 63:557-561.
52. Hanigan MH, Frierson HF Jr, Swanson PE, De Young BR. (1999). Altered expression of gamma-glutamyl transpeptidase in human tumors. Hum Pathol 30:300-305.
53. Hansen RE, Winther Jr. (2009). An introduction to methods for analyzing thiols and disulfides: Reactions, reagents, and practical considerations. Anal Biochem 394:147-158.
54. Hazany S, Hesselink JR, Healy JF, Imbesi SG. (2007). Utilization of glutamate/creatine ratios for proton spectroscopic diagnosis of meningiomas. Neuroradiology 49:121-127.
55. Hedley DW, Nicklee T, Moreno-Merlo F, Pintilie M, Fyles A, Milosevic M, Hill RP. (2005). Relations between non-protein sulfydryl levels in the nucleus and cytoplasm, tumor oxygenation, and clinical outcome of patients with uterine cervical carcinoma. Int J Radiat Oncol Biol Phys 61:137-144.
56. Hengstler JG, Böttger T, Tanner B, Dietrich B, Henrich M, Knapstein PG, Junginger T, Oesch F. (1998). Resistance factors in colon cancer tissue and the adjacent normal colon tissue: glutathione S-transferases alpha and pi, glutathione and aldehyde dehydrogenase. Cancer Lett 128:105-112.
57. Hengstler JG, Pilch H, Schmidt M, Dahlenburg H, Sagemüller J, Schiffer I, Oesch F, Knapstein PG, Kaina B, Tanner B. (2001). Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. Int J Cancer 95:121-127.
58. Hoensch H, Peters WH, Roelofs HM, Kirch W. (2006). Expression of the glutathione enzyme system of human colon mucosa by localisation, gender and age. Curr Med Res Opin 22:1075-1083.
59. Honegger CG, Torhorst J, Langemann H, Kabiersch A, Krenger W. (1988). Quantitative determination of water-soluble scavengers in neoplastic and non-neoplastic human breast tissue. Int J Cancer 41:690-694.
60. Hoppenkamps R, Thies E, Younes M, Siegers CP. (1984). Glutathione and GSH-dependent enzymes in the human gastric mucosa. Klin Wochenschr 62:183-186.
61. Ilonen IK, Räsänen JV, Sihvo EI, Knuuttila A, Salmenkivi KM, Ahotupa MO, Kinnula VL, Salo JA. (2009). Oxidative stress in non-small cell lung cancer: role of nicotinamide adenine dinucleotide phosphate oxidase and glutathione. Acta Oncol 48:1054-1061.
62. Inci E, Civelek S, Seven A, Inci F, Korkut N, Burçax G. (2003). Laryngeal cancer: in relation to oxidative stress. Tohoku J Exp Med 200:17-23.
63. Iscan M, Coban T, Bülbül D, Eke BC, Aygörmez S, Berberoglu U. (1998). Xenobiotic metabolizing and antioxidant enzymes in normal and neoplastic human breast tissue. Eur J Drug Metab Pharmacokinet 23:497-500.
64. Jadhav GK, Bhanumathi P, Uma Devi P, Seetharamaiah T, Vidyasagar MS, Rao KK, Hospet CS, Solomon JG. (1998). Possible role of glutathione in predicting radiotherapy response of cervix cancer. Int J Radiat Oncol Biol Phys 41:3-5.
65. Janot F, Massaad L, Ribrag V, de Waziers I, Beaune PH, Luboinski B, Parise O, Jr., Gouyette A, Chabot GG. (1993). Principal xenobioticmetabolizing enzyme systems in human head and neck squamous cell carcinoma. Carcinogenesis 14:1279-1283.
66. Joncourt F, Buser K, Altermatt H, Bacchi M, Oberli A, Cerny T. (1998). Multiple drug resistance parameter expression in ovarian cancer. Gynecol Oncol 70:176-182.
67. Jones DP. (2006). Redefining oxidative stress. Antioxid Redox Signal 8:1865-1879.
68. Jüngst C, Cheng B, Gehrke R, Schmitz V, Nischalke HD, Ramakers J, Schramel P, Schirmacher P, Sauerbruch T, Caselmann WH. (2004). Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology 39:1663-1672.
69. Kacakci A, Aslan I, Toplan S, Oysu C, Aslan O, Aydemir B. (2009). Significance of the counteracting oxidative and antioxidative systems in the pathogenesis of laryngeal carcinoma. J Otolaryngol Head Neck Surg 38:172-177.
70. Kaur T, Gupta R, Vaiphei K, Kapoor R, Gupta NM, Khanduja KL. (2008a). Interplay between oncoproteins and antioxidant enzymes in esophageal carcinoma treated without and with chemoradiotherapy: a prospective study. Int J Radiat Oncol Biol Phys 70:563-571.
71. Kaur T, Khanduja KL, Gupta R, Gupta NM, Vaiphei K. (2008b). Changes in antioxidant defense status in response to cisplatin and 5-FU in esophageal carcinoma. Dis Esophagus 21:103-107.
72. Kearns PR, Pieters R, Rottier MM, Pearson AD, Hall AG. (2001). Raised blast glutathione levels are associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 97:393-398.
73. Kigawa J, Minagawa Y, Cheng X, Terakawa N. (1998a). Gammaglutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer. Clin Cancer Res 4:1737-1741.
74. Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Cheng X, Okada M, Oishi T, Terakawa N. (1998b). Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer. Cancer 82:697-702.
75. Kolanjiappan K, Ramachandran CR, Manoharan S. (2003). Biochemical changes in tumor tissues of oral cancer patients. Clin Biochem 36:61-65.
76. Kontakiotis T, Katsoulis K, Hagizisi O, Kougioulis M, Gerou S, Papakosta D. (2011). Bronchoalveolar lavage fluid alteration in antioxidant and inflammatory status in lung cancer patients. Eur J Intern Med 22:522-526.
77. Korotkina RN, Matskevich GN, Devlikanova ASh, Vishnevskii AA, Kunitsyn AG, Karelin AA. (2002). Activity of glutathionemetabolizing and antioxidant enzymes in malignant and benign tumors of human lungs. Bull Exp Biol Med 133:606-608.
78. Krepela E, Procházka J, Kárová B, Cermák J, Roubková H. (1997). Cathepsin B, thiols and cysteine protease inhibitors in squamouscell lung cancer. Neoplasma 44:219-239.
79. Kudo H, Mio T, Kokunai T, Tamaki N, Sumino K, Matsumoto S. (1990). Quantitative analysis of glutathione in human brain tumors. J Neurosurg 72:610-615.
80. Kumaraguruparan R, Kabalimoorthy J, Nagini S. (2005). Correlation of tissue lipid peroxidation and antioxidants with clinical stage and menopausal status in patients with adenocarcinoma of the breast. Clin Biochem 38:154-158.
81. Kumaraguruparan R, Subapriya R, Viswanathan P, Nagini S. (2002). Tissue lipid peroxidation and antioxidant status in patients with adenocarcinoma of the breast. Clin Chim Acta 325:165-170.
82. Lafuente A, Maristany M, Arias C, Cuchi A, Lafuente MJ, Molina R, Ballesta A, Trasserra J. (1998). Glutathione and glutathione S-transferases in human squamous cell carcinomas of the larynx and GSTM1 dependent risk. Anticancer Res 18:107-111.
83. Landolt H, Langemann H, Probst A, Gratzl O. (1994). Levels of watersoluble antioxidants in astrocytoma and in adjacent tumor-free tissue. J Neurooncol 21:127-133.
84. Langemann H, Torhorst J, Kabiersch A, Krenger W, Honegger CG. (1989). Quantitative determination of water- and lipid-soluble antioxidants in neoplastic and non-neoplastic human breast tissue. Int J Cancer 43:1169-1173.
85. Lee FY, Vessey A, Rofstad E, Siemann DW, Sutherland RM. (1989). Heterogeneity of glutathione content in human ovarian cancer. Cancer Res 49:5244-5248.
86. Lee KT, Tsai SM, Wang SN, Lin SK, Wu SH, Chuang SC, Wu SH, Ma H, Tsai LY. (2007). Glutathione status in the blood and tissues of patients with virus-originated hepatocellular carcinoma. Clin Biochem 40:1157-1162.
87. Levy RD, Oosthuizen MM, Degiannis E, Greyling D, Hatzitheofilou C. (1999). Glutathione-linked enzymes in benign and malignant oesophageal tissue. Br J Cancer 80:32-37.
88. Lewandowicz GM, Britt P, Elgie AW, Williamson CJ, Coley HM, Hall AG, Sargent JM. (2002). Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer. Gynecol Oncol 85:298-304.
89. Lo HW, Ali-Osman F. (2007). Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr Opin Pharmacol 7:367-374.
90. Louw DF, Bose R, Sima AA, Sutherland GR. (1997). Evidence for a high free radical state in low-grade astrocytomas. Neurosurgery 41:1146-50; discussion 1151.
91. Mekhail-Ishak K, Hudson N, Tsao MS, Batist G. (1989). Implications for therapy of drug-metabolizing enzymes in human colon cancer. Cancer Res 49:4866-4869.
92. Melloni B, Lefebvre MA, Bonnaud F, Vergnenègre A, Grossin L, Rigaud M, Cantin A. (1996). Antioxidant activity in bronchoalveolar lavage fluid from patients with lung cancer. Am J Respir Crit Care Med 154:1706-1711.
93. Mourão de Farias JW, Furtado FS, Guimarães SB, Filho AR, Leitão de Vasconcelos R. (2011). Oxidative stress parameters in women with breast cancer undergoing neoadjuvant chemotherapy and treated with nutraceutical doses of oral glutamine. Acta Cir Bras 26 Suppl 1:82-87.
94. Mueller SG, Trabesinger AH, Boesiger P, Wieser HG. (2001). Brain glutathione levels in patients with epilepsy measured by in vivo (1) H-MRS. Neurology 57:1422-1427.
95. Mulder TPJ, Manni JJ, Roelofs HMJ, Peters WHM, Wiersma A. (1995). Glutathione S-transferases and glutathione in human head and neck cancer. Carcinogenesis 16:619-624.
96. Mun CW, Cho JY, Shin WJ, Choi KS, Eun CK, Cha SS, Lee J, Yang Y, Nam SH, Kim J, Lee SY. (2004). Ex vivo proton MR spectroscopy (1H-MRS) for evaluation of human gastric carcinoma. Magn Reson Imaging 22:861-870.
97. Murawaki Y, Tsuchiya H, Kanbe T, Harada K, Yashima K, Nozaka K, Tanida O, Kohno M, Mukoyama T, Nishimuki E, Kojo H, Matsura T, Takahashi K, Osaki M, Ito H, Yodoi J, Murawaki Y, Shiota G. (2008). Aberrant expression of selenoproteins in the progression of colorectal cancer. Cancer Lett 259:218-230.
98. Murray GI, Burke MD, Ewen SW. (1987). Glutathione localisation in benign and malignant human breast lesions. Br J Cancer 55:605-609.
99. Nagini S, Manoharan S, Ramachandran CR. (1998). Lipid peroxidation and antioxidants in oral squamous cell carcinoma. Clin Chim Acta 273:95-98.
100. Neurohr C, Lenz AG, Ding I, Leuchte H, Kolbe T, Behr J. (2003). Glutamate-cysteine ligase modulatory subunit in BAL alveolar macrophages of healthy smokers. Eur Respir J 22:82-87.
101. O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF. (1996). Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 14:249-256.
102. Oberli-Schrämmli AE, Joncourt F, Stadler M, Altermatt HJ, Buser K, Ris HB, Schmid U, Cerny T. (1994). Parallel assessment of glutathionebased detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer. Int J Cancer 59:629-636.
103. Oliva MR, Ripoll F, Muniz P, Iradi A, Trullenque R, Valls V, Drehmer E, Saez GT. (1997). Genetic alterations and oxidative metabolism in sporadic colorectal tumors form a Spanish community. Mol Carcinogen 18:232-243.
104. Opstad KS, Bell BA, Griffiths JR, Howe FA. (2008). An assessment of the effects of sample ischaemia and spinning time on the metabolic profile of brain tumour biopsy specimens as determined by high-resolution magic angle spinning (1)H NMR. NMR Biomed 21:1138-1147.
105. Opstad KS, Provencher SW, Bell BA, Griffiths JR, Howe FA. (2003). Detection of elevated glutathione in meningiomas by quantitative in vivo 1H MRS. Magn Reson Med 49:632-637.
106. Osmak M, Babic D, Abramic M, Ambriovic A, Milicic D, Eljuga D, Vukovic L. (1997). Glutathione S-transferase activity as an early marker for malignant tumors of corpus uteri. Neoplasma 44:324-328.
107. Ozdemirler G, Pabuççuoglu H, Bulut T, Bugra D, Uysal M, Toker G. (1998). Increased lipoperoxide levels and antioxidant system in colorectal cancer. J Cancer Res Clin Oncol 124:555-559.
108. Parise O Jr, Janot F, Luboinski B, Massaad L, Albin N, Toussaint C, Verjus MA, Bonnay M, Gouyette A, Chabot GG. (1994). Thymidylate synthase activity, folates, and glutathione system in head and neck carcinoma and adjacent tissues. Head Neck 16:158-164.
109. Patel BP, Rawal UM, Dave TK, Rawal RM, Shukla SN, Shah PM, Patel PS. (2007). Lipid peroxidation, total antioxidant status, and total thiol levels predict overall survival in patients with oral squamous cell carcinoma. Integr Cancer Ther 6:365-372.
110. Patel BP, Rawal UM, Rawal RM, Shukla SN, Patel PS. (2008). Tobacco, antioxidant enzymes, oxidative stress, and genetic susceptibility in oral cancer. Am J Clin Oncol 31:454-459.
111. Perquin M, Oster T, Maul A, Froment N, Untereiner M, Bagrel D. (2000). The glutathione-related detoxification pathway in the human breast: a highly coordinated system disrupted in the tumour tissues. Cancer Lett 158:7-16.
112. Perquin M, Oster T, Maul A, Froment N, Untereiner M, Bagrel D. (2001). The glutathione-related detoxification system is increased in human breast cancer in correlation with clinical and histopathological features. J Cancer Res Clin Oncol 127:368-374.
113. Perry RR, Mazetta JA, Levin M, Barranco SC. (1993). Glutathione levels and variability in breast tumors and normal tissue. Cancer 72:783-787.
114. Peters WHM, Wobbes T, Roelofs HMJ, Jansen JBMJ. (1993). Glutathione S-transferases in esophageal cancer. Carcinogenesis 14:1377-1380.
115. Petruzzelli S, Camus AM, Carrozzi L, Ghelarducci L, Rindi M, Menconi G, Angeletti CA, Ahotupa M, Hietanen E, Aitio A. (1988). Long-lasting effects of tobacco smoking on pulmonary drug-metabolizing enzymes: a case-control study on lung cancer patients. Cancer Res 48:4695-4700.
116. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liau LM. (2012). Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol 107:197-205.
117. Redmond SM, Joncourt F, Buser K, Ziemiecki A, Altermatt HJ, Fey M, Margison G, Cerny T. (1991). Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine- DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 51:2092-2097.
118. Roberts JC, Francetic DJ. (1993). The importance of sample preparation and storage in glutathione analysis. Anal Biochem 211:183-187.
119. Rowell NP, McCready VR, Cronin B, Pepper J, Higley B, Burke JF, Tyrrell DA. (1989). 99Tcm-labelled meso-HMPAO and glutathione content of human lung tumours. Nucl Med Commun 10:503-508.
120. Rzymowska J, Dyrda Z. (1993). Enzyme activities and level of SH groups in breast carcinomas. Int J Biochem 25:1331-1334.
121. Sadani GR, Nadkarni GD. (1996). Role of tissue antioxidant defence in thyroid cancers. Cancer Lett 109:231-235.
122. Saroja M, Balasenthil S, Nagini S. (1999). Tissue lipid peroxidation and glutathione-dependent enzyme status in patients with oral squamous cell carcinoma. Cell Biochem Funct 17:213-216.
123. Saydam N, Kirb A, Demir O, Hazan E, Oto O, Saydam O, Güner G. (1997). Determination of glutathione, glutathione reductase, glutathione peroxidase and glutathione S-transferase levels in human lung cancer tissues. Cancer Lett 119:13-19.
124. Schäfer C, Fels C, Brucke M, Holzhausen HJ, Bahn H, Wellman M, Visvikis A, Fischer P, Rainov NG. (2001). Gamma-glutamyl transferase expression in higher-grade astrocytic glioma. Acta Oncol 40:529-535.
125. Schipper DL, Wagenmans MJ, Peters WH, Wils JA, Wagener DJ. (2000). Glutathione S-transferases and iododeoxyuridine labelling index during chemotherapy of gastric cancer. Anticancer Res 20:1705-1710.
126. Siegers CP, Böse-Younes H, Thies E, Hoppenkamps R, Younes M. (1984). Glutathione and GSH-dependent enzymes in the tumorous and nontumorous mucosa of the human colon and rectum. J Cancer Res Clin Oncol 107:238-241.
127. Sihvo EI, Ruohtula T, Auvinen MI, Koivistoinen A, Harjula AL, Salo JA. (2003). Simultaneous progression of oxidative stress and angiogenesis in malignant transformation of Barrett esophagus. J Thorac Cardiovasc Surg 126:1952-1957.
128. Sihvo EI, Salminen JT, Rantanen TK, Rämö OJ, Ahotupa M, Färkkilä M, Auvinen MI, Salo JA. (2002). Oxidative stress has a role in malignant transformation in Barrett's oesophagus. Int J Cancer 102:551-555.
129. Singh S, Khan AR, Gupta AK. (2012). Role of glutathione in cancer pathophysiology and therapeutic interventions. J Exp Ther Oncol 9:303-316.
130. Skrzydlewska E, Kozuszko B, Sulkowska M, Bogdan Z, Kozlowski M, Snarska J, Puchalski Z, Sulkowski S, Skrzydlewski Z. (2003). Antioxidant potential in esophageal, stomach and colorectal cancers. Hepatogastroenterology 50:126-131.
131. Skrzydlewska E, Stankiewicz A, Sulkowska M, Sulkowski S, Kasacka I. (2001). Antioxidant status and lipid peroxidation in colorectal cancer. J Toxicol Environ Health Part A 64:213-222.
132. Skrzydlewska E, Sulkowski S, Koda M, Zalewski B, Kanczuga-Koda L, Sulkowska M. (2005). Lipid peroxidation and antioxidant status in colorectal cancer. World J Gastroenterol 11:403-406.
133. Somashekar BS, Kamarajan P, Danciu T, Kapila YL, Chinnaiyan AM, Rajendiran TM, Ramamoorthy A. (2011). Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues. J Proteome Res 10:5232-5241.
134. Sprem M, Babic D, Abramic M, Vrhovec I, Skrk J, Milicic D, Ambriovic Ristov A, Kalafatic D, Osmak M. (2001). Glutathione and glutathione S-transferases as early markers for ovarian carcinomas: case series. Croat Med J 42:624-629.
135. Sreerama L, Sladek NE. (1997). Cellular levels of class 1 and class 3 aldehyde dehydrogenases and certain other drug-metabolizing enzymes in human breast malignancies. Clin Cancer Res 3:1901-1914.
136. Sreerama L, Sládek NE. (2001). Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization of cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 47:255-262.
137. Subapriya R, Kumaraguruparan R, Ramachandran CR, Nagini S. (2002). Oxidant-antioxidant status in patients with oral squamous cell carcinomas at different oral sites. Clin Biochem 35:489-493.
138. Suess E, Malessa S, Ungersböck K, Kitz P, Podreka I, Heimberger K, Hornykiewicz O, Deecke L. (1991). Technetium-99m-d,1- hexamethylpropyleneamine oxime (HMPAO) uptake and glutathione content in brain tumors. J Nucl Med 32:1675-1681.
139. Tanner B, Hengstler JG, Dietrich B, Henrich M, Steinberg P, Weikel W, Meinert R, Kaina B, Oesch F, Knapstein PG. (1997). Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer. Gynecol Oncol 65:54-62.
140. Toussaint C, Albin N, Massaad L, Grunenwald D, Parise O, Jr., Morizet J, Gouyette A, Chabot GG. (1993). Main drug- and carcinogenmetabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues. Cancer Res 53:4608-4612.
141. Vukovic V, Nicklee T, Hedley DW. (2000). Microregional heterogeneity of non-protein thiols in cervical carcinomas assessed by combined use of HPLC and fluorescence image analysis. Clin Cancer Res 6:1826-1832.
142. Wong DY, Hsiao YL, Poon CK, Kwan PC, Chao SY, Chou ST, Yang CS. (1994). Glutathione concentration in oral cancer tissues. Cancer Lett 81:111-116.
143. Woolston CM, Al-Attar A, Storr SJ, Ellis IO, Morgan DA, Martin SG. (2011). Redox protein expression predicts radiotherapeutic response in early-stage invasive breast cancer patients. Int J Radiat Oncol Biol Phys 79:1532-1540.
144. Wright AJ, Fellows GA, Griffiths JR, Wilson M, Bell BA, Howe FA. (2010). Ex-vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour biomarkers. Mol Cancer 9:66.
145. Yeh CC, Hou MF, Wu SH, Tsai SM, Lin SK, Hou LA, Ma H, Tsai LY. (2006). A study of glutathione status in the blood and tissues of patients with breast cancer. Cell Biochem Funct 24:555-559.
146. Zengin E, Atukeren P, Kokoglu E, Gumustas MK, Zengin U. (2009). Alterations in lipid peroxidation and antioxidant status in different types of intracranial tumors within their relative peritumoral tissues. Clin Neurol Neurosurg 111:345-351.